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Abstract:  Acute liver failure is a sudden decline in liver function with jaundice, coagulopathy (INR ≥ 1.5) and hepatic 
encephalopathy in patients with no history of liver disease and it emerges in less than 26 weeks. The interval 
between the occurrence of yellow symptoms and hepatic encephalopathy of less than 7 days is hyperacute, 
8-28 days is called acute, and more than 28 days but less than 26 weeks is called subacute. If the interval is 
more than 6 months, it is called chronic liver failure. The etiology of most cases is due to the use of 
acetaminophen. The treatment of ALF should be performed in the ICU to minimize the risk of infection, 
cerebral edema, bleeding, respiratory failure, and other organ function disorders. The prognosis of ALF 
depends on the degree of encephalopathy, prolongation of prothrombin time, serum bilirubin level, and 
kidney function. 
1 INTRODUCTION 
Acute liver failure (ALF) is one of the 
manifestations of hepatocellular failure, where liver 
function declines suddenly without a prior liver 
disease. Symptoms include jaundice, coagulopathy, 
and damage to many organs (Khashab, Tector, & 
Kwo, 2007). The number of ALF cases is about 10 
to 1 million people each year (Bernal & Wendon, 
2013) 2,000-2,800 cases of which are found in the 
United States and about 15% cases are undetectable 
(Shahani, 2016).  
ALF can be caused by many things. The most 
common cause in the United States and Europe is 
the use of acetaminophen, while viral hepatitis is the 
cause in Japan and Asia (Khashab et al., 2007; 
Sugawara, Nakayama, & Mochida, 2012). Finding 
the cause of ALF and addressing the causes will 
provide a better prognosis even though the ALF 
mortality rate in the world is still relatively high 
(Blackmore & Bernal, 2015). 
Management of ALF is quite complex and 
depends on the cause. If the healing process cannot 
take place then liver transplantation is the treatment 
option used in Europe and the United States, 
whereas Japan has the therapy choice of plasma 
exchange and hemodiafiltration (Sugawara et al., 
2012). 
Based on the data, it is important for a specialist 
in internal medicine to know more about ALF and 
its treatment. Early detection of ALF, its causes and 
proper treatment are expected to reduce ALF 
mortality. This report discusses ALF including 
definition, classification, pathophysiology, etiology, 
diagnosis, management, and prognosis. This paper is 
expected to help specialists in internal medicine to 
better understand and manage ALF. 
2 DEFINITION  
ALF, commonly referred to as fulminant liver 
failure is a hepatic encephalopathy syndrome and 
bleeding that occurs due to malfunction of liver cells 
caused by liver cell death within the first 26 weeks 
without previous liver disease (Bernal & Wendon, 
2013; Schilsky, Honiden, Arnott, & Emre, 2009; 
Sugawara et al., 2012). ALF is a sudden decline in 
liver function with coagulopathy (INR ≥ 1.5) and 
hepatic encephalopathy in patients with no previous 
liver disease and it emerges in less than 26 weeks 
(Setiawan, 2015).  
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3 CLASSIFICATION 
ALF classification is divided into three based on the 
interval between the occurrence of yellow symptoms 
and hepatic encephalopathy, i.e., less than 7 days is 
hyperacute, 8-28 days is called acute, and more than 
28 days but less than 26 weeks is called subacute  
(Setiawan, 2015). More details are given in Table 1. 
Table 1: ALF Classification. 
 Hyperacute Acute Subacute
Jaundice-
encephalop
athy 
0-1 week 1-4 
weeks 
5-26 weeks 
Increased 
prothrombi
n time 
Severe Moderat
e 
Mild 
Edema Severe Moderat
e 
Mild 
Prognosis Good Moderat
e 
Bad 
Cause Acetamino
phen, 
hepatitis A 
& E 
Hepatitis 
B 
Non-
acetaminoph
en, 
seronegative
/intermediat
e hepatitis
4 PATHOPHYSIOLOGY 
Damage to liver cells is caused by direct damage and 
response by the immune system through activation 
of monocytes, macrophages, dendritic cells, 
leukocytes, NK cells and HCV (natural killer T) 
cells. Injury to hepatocytes will cause damage and 
liver cell death through necrosis and apoptosis. 
Apoptosis occurs when ATP is available. If ATP is 
not sufficient, necrosis will happen (Schilsky et al., 
2009). Cells with necrosis will suffer damage to the 
integrity of the cell membrane; thus, it ruptures and 
releases cytosolic proteins such as lactate 
dehydrogenase (LDH), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and 
ferritin  (Schilsky et al., 2009).  
The discharge of cell and ROS contents will 
activate stellate cells in the liver which attract and 
activate tissue macrophages through CC-chemokine 
ligand 2 (CCL2)-CC-chemokine receptor 2 (CCR2). 
Then, it engulfs necrotic cells which undergo 
apoptosis. Stellate and macrophage cells also release 
proinflammatory cytokines such as IL-6, TNF, IL-
1β, and TGF β, attracting T cells and neutrophils. 
TGF β causes stellate cell differentiation into 
myofibroblasts. Platelet-derived growth factor 
(PDGF) causes proliferation of myofibroblasts. 
Myofibroblasts produce α-smooth muscle actin 
(αSMA) and collagen I. Macrophages have a latent 
capacity to decrease the scar matrix through 
metalloproteinase (MMP) matrix secretion; 
however, protease activity is inhibited by the 
production of tissue inhibitor of metalloproteinase 
by myofibroblasts and macrophages which results in 
progressive matrix deposition and the accumulation 
of scars. Improved intestine permeability and liver 
lipopolysaccharide (LPS)-Toll-like receptor 4 
(TLR4) signaling cause fibrogenesis of liver stellate 
cells with active TLR4. It produces chemokines and 
express adhesion molecules that recruit macrophages 
to the site of injury. Chronic inflammation and 
interactions between cell matrixes lead to 
fibrogenesis (Pellicoro, et al., 2014). 
5 ETIOLOGY 
5.1 Virus 
Hepatitis A and E viruses are the most common 
cause of acute liver failure with a mortality up to 
50% in developing countries, whereas hepatitis B is 
the leading cause in Asian and Mediterranean 
countries (Bernal & Wendon, 2013). In addition to 
the hepatitis virus, herpes simplex, herpes zoster, 
varicella zoster, CMV, Epstein Barr virus, and 
parvovirus can also cause acute liver failure 
(Shahani, 2016; Thayapararajah, Gulka, Al-Amri, 
Das, & Young, 2013).  
5.2 Use of drugs 
Use of drugs that cause acute liver damage occurs in 
50% of cases in the United States (Bernal & 
Wendon, 2013; Ichai & Samuel, 2008). 
Acetaminophen causes more damage to the central 
liver zone and port system (Chen et al., 2015). 
5.3 Other causes 
Other causes of ALF include patients with heart 
problems, respiratory failure, sepsis, circulatory 
disorders, hypoxia hepatitis or acute ischemia 
hepatocellular injury (Bernal & Wendon, 2013), and 
misuse of MDMA (3,4-methylenedioxy-N-
methylamphetamine, or cocaine) at a young age 
(Ichai & Samuel, 2008). Budd Chiari syndrome will 
cause obstruction in the blood liver flow resulting in 
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acute liver failure (Schilsky et al., 2009). Fungus 
amanita causes vomiting, diarrhea, impaired liver 
function, and other organs. Wilson disease is a 
condition when a buildup of copper causes liver 
damage, usually accompanied by hemolytic 
nonimmune anemia (Jin, Chen, Jiang, & Lu, 2012). 
6 DIAGNOSIS 
It is necessary to ask about the history of drug usage 
especially acetaminophen, hepatotoxic substances, 
fever, signs of hepatitis, and history of previous 
disease during anamnesis. It is necessary to evaluate 
the patient's mental status, hepatic and lien tackling, 
presence or absence of ascites, jaundice, as well as 
signs of chronic liver failure, e.g. spider nevi, 
gynecomastia, and palmar erythema on physical 
examination (Jin et al., 2012). Examination of the 
mental status performed includes awareness, size 
and comparison of the left-right pupil, pupil reflex 
quality, and the presence or absence of clonus. 
Evaluation of encephalopathy uses West Haven 
Criteria (Schachinger et al., 2009). 
Blood tests required are complete blood, 
hemostasis physiology, liver function, kidney 
function, sugar levels and electrolytes. Analysis of 
blood gas and virological (hepatitis, or other 
viruses), autoimmune markers, microbiology (blood 
cultures, urine, sputum), pregnancy tests, and 
toxicology also need to be examined. Radiological 
examination is performed to determine the size and 
circumstances of liver, lien, artery and hepatic vein, 
the presence of tumors, the state of other abdominal 
organs with an abdominal ultrasound, head CT scan, 
and thorax photographs. It is called acute liver 
failure if the following symptoms occur within 8-26 
weeks of the symptoms of hepatitis occurring 
(Setiawan, 2015; Sugawara et al., 2012). 
 
 
 
 
 
 
7 MANAGEMENT 
7.1 Metabolism 
Patients with acute liver failure experience 
hypoglycemia due to reduced glycogen storage, 
failure of gluconeogenesis, and increased insulin 
secretion; thus, intravenous glucose is administered. 
Intravenous fluids also need to be taken into 
account, and prevention of hyponatremia should be 
done because it can cause cerebral edema. These 
conditions are very influential on the nutrition of 
patients; thus, there is a need to pay attention to the 
patient's diet. The dietary administration is in 
accordance with the International Society for 
Hepatic Encephalopathy and Nitrogen Metabolism 
that includes the number of calories, protein, and 
mode of administration. Calories given are 5-30 
kcal/kg BW/day (Schilsky et al., 2009). Dietary 
protein given is 1-1.5 g/kg BW/day with monitoring 
of blood ammonia levels, and proteins are needed 
for immune system formation and increased 
catabolism (Bernal & Wendon, 2013). An example 
of an EH diet in Dr. Soetomo General Hospital 
Surabaya can be seen in Table 2. 
7.2 Infection 
The greatest cause of death is an infection because 
the liver cells are damaged and bacterial 
translocation occurs. The most common infections 
invade the lungs, urinary tract, and blood. The most 
common causes are Staphylococcus, Streptococcus, 
and enteric gram-bacilli, and fungal infections, 
particularly candida. Antibiotics given are empirical 
antibiotics, broad spectrum for positive and negative 
gram, the third generation of cephalosporins, and 
while awaiting the results of culture, vancomycin 
(Schilsky et al., 2009; Shahani, 2016). If the 
condition does not improve, then antifungal 
administration should be considered. The choice of 
antifungal is fluconazole with a dose of 10 mg/day 
or amphotericin B 20 mg/day. Administration of an 
amphotericin nebulizer (30 mg in 5 ml of 0.9% 
saline) may be given if there are respiratory 
infections due to fungi (Kayaalp, Ersan, & Yilmaz, 
2014). 
Table 2: Example of EH diet in Dr. Soetomo General Hospital Surabaya Indonesia. 
Type Calories Proteins Administration Mode Indication 
Parentera
l 
Diet EH 1  1,700 kcal 7% (30 g)  orally hepatic precoma is resolved AARC
Diet EH 2  1,400 kcal 5% (18 g)  orally hepatic precoma (I) AARC
Diet EH 3  1,200 kcal 1% (4 g)  enteral hepatic coma (II, III, IV) AARC
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7.3 Heart Failure and Respiratory 
Disorders 
Lack of intake, vomiting, and vasodilation can cause 
hypotension. The porta pressure will increase, blood 
collection occurs in the splanchnic so that venous 
return decreases, arterial dilatation occurs due to 
disrupted blood vessel muscle and sepsis, and this 
accumulation will cause hypotension. The therapy is 
aimed at improving tissue perfusion and oxygen 
adequacy. The liquid selected for resuscitation is 
normal. Dopamine and norepinephrine can increase 
blood flow to the liver and cardiac output; however, 
they have a tachycardia effect. Dopamine is a better 
option in this case (Setiawan, 2015). Dobutamine is 
used in the event of a left ventricular disorder, but it 
can lead to worse hypotension due to arterial 
dilatation. If there is no intracranial pressure gauge, 
then the target of therapy is MAP > 80 mmHg. If 
arrhythmia occurs, vasopressin is given as many as 
0.04 U/minute and norepinephrine is gradually 
reduced. Cardiovascular cardiac instability may lead 
to relative adrenal insufficiency, hydrocortisone 
therapy given is 200-300 mg/day and the dose is 
divided (Bernal & Wendon, 2013). 
7.4 Neurological disorders 
The decrease in the amount of ammonia absorption 
by the brain and decrease in the increase of 
intracranial pressure are achieved by administration 
of osmotherapy (intravenous hypertonic saline fluid 
with 20 ml of 30% NaCl or 200 ml of 3% NaCl, the 
sodium serum is maintained at 145-155 mmol per 
liter, 2 ml of 20% mannitol per kg body weight or 
0.5-1g per kg body weight, serum osmolarity of < 
320 mOsm per liter) (Bernal & Wendon, 2013; Jin et 
al., 2012; Setiawan, 2015). 
The head being held up 300 can facilitate 
cerebrospinal flow and reduce intracranial pressure. 
The action to move the neck should be avoided to 
prevent the occurrence of jugular venous 
compression. Hypothermia (32-34oC) can decrease 
metabolism and seizure events, normalize perfusion 
to the brain, decrease ammonia to the brain, and 
stabilize hemodynamics; meanwhile, the side-effects 
are arrhythmias, bleeding, electrolyte imbalance, 
hyperglycemia, and metabolic disorders. Rewarming 
is carried out with an increase in the temperature at 
1°C/hour to 1°C/day (Jin et al., 2012; Schilsky et al., 
2009). 
Administration of indomethacin (0.5 mg/kg body 
weight) may help to overcome encephalopathy 
(Bernal & Wendon, 2013). Hyperventilation can be 
performed to reduce intracranial pressure. Patients 
with hepatic encephalopathy of grade 3 or more 
should be intubated with appropriate sedation and 
analgesics (Propofol and fentanyl). Propofol is 
preferred because of its shorter duration of action, 
and it may decrease cerebrospinal fluid production 
and decrease intracranial pressure. Preferably pain 
therapy is fentanyl over morphine or meperidine, 
because the active metabolism of morphine and 
meperidine may decrease the seizure threshold 
(Schilsky et al., 2009). 
7.5 Impaired kidney function 
Kidney failure can occur in 50% of cases of acute 
liver failure, especially in elderly patients. This can 
be due to several causes of GHA being nephrotoxic 
such as acetaminophen, sulfonamide, halothane, 
toxic fungal poisons, and hypoxic hepatitis. It causes 
acute tubular necrosis and hepatorenal syndrome. It 
is called acute tubular necrosis if sodium in urine 
was > 20 mmol/L (Bernal & Wendon, 2013; 
Schilsky et al., 2009). Hemodialysis may be an 
option if progressive acute renal failure occurs 
(Schilsky et al., 2009; Setiawan, 2015).  
7.6 Bleeding 
Prolongation of prothrombin time occurs due to 
synthesis disorders and increased procoagulation 
factor requirements. Meanwhile, the cause of 
thrombocytopenia is still not recognized clearly. 
Vitamin K is administered at a dose of 10 mg 
intravenously or subcutaneously. Platelet transfusion 
is performed if the platelets are < 10,000 or an 
invasive action is performed (50,000-70,000) 
(Schilsky et al., 2009; Setiawan, 2015). The 
exchange of plasmapheresis, as well as the provision 
of recombinant factor VIIa, may be the treatment 
option (Stravitz & Kramer, 2009). If FFP transfusion 
fails to correct the prothrombin time and platelet 
amount (> 50,000) then a recombinant factor of 7 
(40 mg/kg) is preferred. Patients with 
hypofibrinogenemia (< 100 mg/dl) can be given 
cryoprecipitate (Schilsky et al., 2009). 
One option of ALF therapy is liver 
transplantation. Life success rate in the first year is 
about 79% and 72% in the first 5 years. Death is 
usually caused by an infection in the first 3 months, 
neurological disorders, and the rejection of donor 
organs (Bernal & Wendon, 2013; Schilsky et al., 
2009).  The risk of death will increase in elderly 
patients and those who receive organs from donors 
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with different blood types (Bernal & Wendon, 2013; 
Setiawan, 2015). 
8 PROGNOSIS 
Factors influencing the success of therapy in ALF 
patients include the degree of encephalopathy, 
patient age, and cause of ALF. The success in 
encephalopathy degree I-II is about 65-70%; 
however, degree IV has success of less than 20%. 
The survival rate is 50% without a liver transplant in 
ALF patients due to acetaminophen, hepatitis A, 
ischemia hepatitis, and pregnancy; meanwhile, the 
other survival rate is below 25% (Gotthardt et al., 
2007). 
9 SUMMARY 
ALF is a sudden decline in liver function with 
jaundice, coagulopathy (INR ≥ 1.5), and hepatic 
encephalopathy in patients without previous liver 
disease and it emerges in less than 26 weeks. The 
interval between the occurrence of yellow symptoms 
and hepatic encephalopathy of less than 7 days is 
hyperacute, 8-28 days is called acute, and more than 
28 days but less than 26 weeks is called subacute. If 
the interval is more than 6 months, it is called 
chronic liver failure. The etiology of most causes is 
due to the use of acetaminophen. The treatment of 
ALF should be conducted in the ICU to minimize 
the risk of infection, cerebral edema, bleeding, 
respiratory failure and other organ function 
disorders. The prognosis of ALF depends on the 
degree of encephalopathy, prolongation of 
prothrombin time, serum bilirubin level, and kidney 
function. 
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